Talactoferrin Stimulates Wound Healing With Modulation of Inflammation

Journal of Surgical Research

Volumn 149, Issue 2, 2008, Pages 278-286

  Engelmayer, Jose ^a   Blezinger, Paul ^a   Varadhachary, Atul ^a  

^a AGENNIX INC   (United States)

Author keywords

inflammation; lactoferrin; talactoferrin; wound healing

Indexed keywords

BECAPLERMIN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; TALACTOFERRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; DIABETES MELLITUS; DIABETIC ULCER; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN FIBROBLAST; SKIN ULCER; WOUND; WOUND CLOSURE; WOUND HEALING;

ADMINISTRATION, CUTANEOUS; ANIMALS; DIABETES COMPLICATIONS; HUMANS; INFLAMMATION MEDIATORS; JURKAT CELLS; LACTOFERRIN; MALE; MICE; MICE, INBRED ICR; SOFT TISSUE INJURIES; WOUND HEALING;

EID: 51049104078     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.12.754     Document Type: Article

References (28)

1. Vorland L.H. Lactoferrin: A multifunctional glycoprotein. APMIS 107 (1999) 971
2. Engelmayer J., and Varadhachary A. Properties of recombinant human lactoferrin and potential application to enhance healing of diabetic wounds. Wounds 15 (2003) 294
3. Singer A.J., and Clark R.A. Cutaneous wound healing. N Engl J Med 341 (1999) 738
4. Diegelmann R.F., and Evans M.C. Wound healing: An overview of acute, fibrotic, and delayed healing. Front Biosci 9 (2004) 283
5. Moore K., Ruge F., and Harding K.G. T lymphocytes and the lack of activated macrophages in wound margin biopsies from chronic leg ulcers. Br J Dermatol 137 (1997) 188
6. Loots M.A., Lamme E.N., Zeegelaar J., et al. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 111 (1998) 850
7. Rosner K., Ross C., Karlsmark T., et al. Immunohistochemical characterization of the cutaneous cellular infiltrate in different areas of chronic leg ulcers. APMIS 103 (1995) 293
8. Herrick S.E., Sloan P., McGurk M., et al. Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am J Pathol 141 (1992) 1085
9. Duraisamy Y., Slevin M., Smith N., et al. Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: Possible relevance to wound healing in diabetes. Angiogenesis 4 (2001) 277
10. Claudy A.L., Mirshahi M., Soria C., et al. Detection of undegraded fibrin and tumor necrosis factor-alpha in venous leg ulcers. J Am Acad Dermatol 25 (1991) 623
11. Sorimachi K., Akimoto K., Hattori Y., et al. Activation of macrophages by lactoferrin: Secretion of TNF-α, IL-8, and NO. Biochem Mol Biol Int 43 (1997) 79
12. Edde L., Hipolito R.B., Hwang F.F., et al. Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Gastrointest Liver Physiol 281 (2001) G1140
13. Artym J., Zimecki M., and Kruzel M.L. Effects of lactoferrin on IL-6 production by peritoneal and alveolar cells in cyclophosphamide-treated mice. J Chemother 16 (2004) 187
14. Varadhachary A., Wolf J.S., Petrak K., et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer 111 (2004) 398
15. Montesinos M.C., Gadangi P., Longaker M., et al. Wound healing is accelerated by agonists of adenosine A2 (G α s-linked) receptors. J Exp Med 186 (1997) 1615
16. Robson M.C., Phillips T.J., Falanga V., et al. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 9 (2001) 347
17. Gentzkow G.D., Iwasaki S.D., Hershon K.S., et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 19 (1996) 350
18. Tsuboi R., Shi C.M., Rifkin D.B., et al. A wound healing model using healing-impaired diabetic mice. J Dermatol 19 (1992) 673
19. Werner S., Breeden M., Hübner G., et al. Induction of keratinocyte growth factor expression is reduced and delayed during wound healing in the genetically diabetic mouse. J Invest Dermatol 103 (1994) 469
20. Sato Y., Ohshima T., and Kondo T. Regulatory role of endogenous interleukin-10 in cutaneous inflammatory response of murine wound healing. Biochem Biophys Res Commun 265 (1999) 194
21. Wetzler C., Kampfer H., Pfeilschifter J., et al. Keratinocyte-derived chemotactic cytokines: Expressional modulation by nitric oxide in vitro and during cutaneous wound repair in vivo. Biochem Biophys Res Commun 274 (2000) 689
22. Jackman S.H., Yoak M.B., Keerthy S., et al. Differential expression of chemokines in a mouse model of wound healing. Ann Clin Lab Sci 30 (2000) 201
23. Angele M.K., Knoferl M.W., Ayala A., et al. Trauma-hemorrhage delays wound healing potentially by increasing proinflammatory cytokines at the wound site. Surgery 126 (1999) 279
24. Goren I., Kampfer H., Podda M., et al. Leptin and wound inflammation in diabetic ob/ob mice: Differential regulation of neutrophil and macrophage influx and a potential role for the scab as a sink for inflammatory cells and mediators. Diabetes 52 (2003) 2821
25. Lyons T.E., Miller M.S., Serena T., et al. Talactoferrin α, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: A Phase I/II clinical study. Am J Surg 193 (2007) 49
26. Weiman J.T. Clinical efficacy of becaplermin (rhPDGF-BB). Am J Surg 176 2A Suppl (1998) 74S
27. Bakker K., Rauwerda J.A., and Schaper N.C. Introduction. Diabetes Metab Res Rev 16 1 Suppl (2000) S1
28. LeFrock J.L., and Joseph W.S. Bone and soft-tissue infections of the lower extremities in diabetics. Clin Podiatr Med Surg 12 (1995) 87